Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6 - Test2 - elhamkhani - TriplyDB

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

http://www.wikidata.org/entity/Q24563585

about

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice Osteoimmunology: interactions of the bone and immune system Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1 The molecular mechanism of osteoclastogenesis in rheumatoid arthritis The Alternative Faces of Macrophage Generate Osteoclasts Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review Historically significant events in the discovery of RANK/RANKL/OPG Multiple organ dysfunction and systemic inflammation after spinal cord injury: a complex relationship The biology and clinical evidence of microfracture in hip preservation surgery Transmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cells Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses The anti-aging effects of LW-AFC via correcting immune dysfunctions in senescence accelerated mouse resistant 1 (SAMR1) strain Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update The Kampo medicine Rokumigan possesses antibiofilm, anti-inflammatory, and wound healing properties.Rheumatoid Arthritis Fibroblast-like Synoviocyte Suppression Mediated by PTEN Involves Survivin Gene Silencing.Soluble cytokine receptors: basic immunology and clinical applications.The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells.Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene Anti-interleukin 6 receptor antibody treatment in rheumatic disease.Addition of aerobic exercise to a weight loss program increases BMD, with an associated reduction in inflammation in overweight postmenopausal women Interleukin-6 and rheumatic diseases.Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow.Role of the osteoclast at the bone-implant interface.Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.gp130 at the nexus of inflammation, autoimmunity, and cancer.The therapeutic potential of interleukin-6 hyperagonists and antagonists.Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis.gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells Population differences in proinflammatory biology: Japanese have healthier profiles than Americans.The biochemical origin of pain--proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3--a unifying law of pain SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis.The paradigm of IL-6: from basic science to medicine

P2860

Q24630541-41718738-242A-41ED-8FCE-7B1DA1C16BBE Q24642117-16A7FB20-4D20-49B0-AC87-2810502FC921 Q24655113-5310BF95-E77A-438A-8153-90D15E468292 Q24804802-BB1C8110-FF78-4850-A0F0-412CCE598BCC Q24806322-242E719A-DEC8-4330-98AB-ECBB9FE13EDD Q26765491-C509AD89-1F9C-4F27-A5E6-55AB2D98A7C0 Q26774874-F3C81C15-EDEB-42D1-9456-028F6BAEC068 Q27027402-21DA2E85-2037-4796-858A-1A31B8BF6F2A Q28066958-25FFD048-6EF1-4093-8C8C-DEF18399B27B Q28072782-BB02C3B9-934C-4A5F-99B3-8EFD15B1990E Q28255702-D1F67E5A-3CFE-4671-B34D-39E33F3A31D1 Q28273257-123F2CC0-B01B-4CBA-9566-4721794168DA Q28366650-A1EDC40C-77FC-4CAD-ABA8-853E3C4B45BD Q28634282-1CE4C866-18DF-42E1-8A97-91C9DA189BAF Q30819335-1CCFA908-1F65-4EF9-AE2C-8234FDE0FCD4 Q30827854-83859A9A-C9B7-47CE-8195-42AB1959C393 Q33285746-28ED7EB0-A72B-41B2-9519-631B1DB58C61 Q33586501-D719E0CF-0428-4965-881B-372727EEFF10 Q33615873-524E20EC-33C6-452E-8189-F357E6B7329C Q33673624-36708695-F0D8-4BB6-B861-355926A31035 Q33688222-F8EE7583-85E9-460E-81D1-1AA90E6C88C8 Q33731751-4B997798-FB56-417C-8378-9FC3E7805EF5 Q33767224-1F5731AE-E63F-40B8-8DB0-5E20E4F2DBE6 Q33800888-1EE194F9-071F-4BF5-A217-310AD068CC41 Q33853660-9D757AA1-9396-46B7-BAA5-C0839219CCAE Q34071253-9A15AFD1-46C0-4576-A003-FA1A8ECC0AE9 Q34080333-5F06A542-0F72-49EE-B905-917401334F05 Q34160235-0C1DE619-FD87-46E5-A08A-C781B3AC33C5 Q34183981-388082C8-8BEC-4770-B8E1-5A8BB2A71212 Q34200518-9296999E-692D-401E-A367-EA08D2D0B635 Q34270015-F90CAAF3-DC28-4A71-99B3-27500B7D9207 Q34343286-38AE83AD-AE36-4CBF-A11E-3AD1B2ABD011 Q34378756-F1CA039A-CC9E-4E7C-9658-489D2BBFC379 Q34430168-956B264B-573F-48BE-A202-A801AE262B16 Q34501230-8EDEF577-A674-441F-8547-6EBCF74DA0D1 Q34510302-6177AF94-118E-4FAA-B272-53B744FCC141 Q34574670-907DCE5F-B92E-41D8-9AD9-0BFFE7B01D96 Q34604663-7322C9B0-7E5B-48BD-B56D-F633931F3395 Q34619592-8DC2A994-66EA-4D3F-81B5-FE7F0FD84B9A Q34731226-305D3F78-431D-47A1-8CD9-9092E46FC5DD

P2860

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

http://www.wikidata.org/entity/Q24563585

description

1993 nî lūn-bûn

@nan

1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@ast

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@en

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@nl

type

label

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@ast

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@en

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@nl

prefLabel

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@ast

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@en

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@nl

P1433

Q24563585-88EE25A8-A866-4A3C-85BB-4AD4110E44D0

P1476

Q24563585-204B969B-F90A-4824-B307-A82BC308F4CB

P2093

Q24563585-2092ACCC-C178-423A-9439-03018609E038

Q24563585-344E6B07-42B3-463B-B3F9-ACF22DD8CBB1

Q24563585-3A9B2757-3B84-479D-AD56-D60FDF7C62FD

Q24563585-766E90B5-AD80-45DF-898F-56D4FDA45165

Q24563585-7B543BFA-AE82-4952-9161-EEFC023C37E2

Q24563585-7D4F14F9-42BE-4535-8F7A-63F08F624A6A

Q24563585-964BEF87-18DB-45FB-A542-D1050F546629

Q24563585-A506B392-15ED-443A-9396-122CDEBB2E73

Q24563585-AB0FAA04-3346-4111-929E-6C7ECA8487CF

Q24563585-D2800C0B-8BE4-4612-8732-18F49D320B07

P2860

Q24563585-073598E8-7F46-4A82-983C-FC5667467C50

Q24563585-25C2C402-DD0A-44D0-86A0-6A46718376A1

Q24563585-2BFC8193-843A-4CF7-8BC5-FC20C0005533

Q24563585-36D666AC-E084-49A5-A3DD-5CEFA6250471

Q24563585-3A364400-E2B5-432E-AEF7-57724644A067

Q24563585-4BCFA33D-6C74-426C-A516-07DD41808CF8

Q24563585-50F1778A-6002-4405-A04F-A63DDE6541EA

Q24563585-52C8ACBC-DA42-46A6-B96E-F2C17329F5D4

Q24563585-66549A40-4E9A-431F-BAA8-DD4B3AE9EC4A

Q24563585-83238D3E-40E0-4CE3-AADB-AFB4EFED0D97

P304

Q24563585-DAA1DDDB-885A-41EC-A07A-5EEA27F89404

P31

Q24563585-BA1BF00F-5992-4A46-8F0F-39D7046D36E1

P3181

Q24563585-70BCAD87-F7E2-48AE-8E08-1AC15CDD64CC

P356

Q24563585-831AAD60-D796-44B8-AEA9-768C995AE5F0

P407

Q24563585-57CA2035-CF9D-4936-9C46-8A31530DAA13

P433

Q24563585-5932D346-4F86-42E0-B03B-638E595C6B98

P478

Q24563585-64CB0954-84C1-49DD-BEF2-9CC002B64DAF

P577

Q24563585-51839D0D-3233-4D90-AAF1-5CB49136A497

P5875

Q24563585-E9CFF938-7842-482B-A6B4-1CF74010DDE0

P698

Q24563585-2590DA00-A4A3-4FE9-9DF9-5859E048929D

P921

Q24563585-2f324ae1-e738-43d2-a5b6-3b24aa3d376e

P932

Q24563585-A3A16B62-95DC-48F5-A07C-DD442F0E8B10

P3181

P356

PNAS.90.24.11924

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

@en

P2093

C Miyaura

http://www.w3.org/2001/XMLSchema#string

K Kumaki

http://www.w3.org/2001/XMLSchema#string

N Takahashi

http://www.w3.org/2001/XMLSchema#string

N Udagawa

http://www.w3.org/2001/XMLSchema#string

S Tanaka

http://www.w3.org/2001/XMLSchema#string

T Taga

http://www.w3.org/2001/XMLSchema#string

T Tamura

http://www.w3.org/2001/XMLSchema#string

Y Koishihara

http://www.w3.org/2001/XMLSchema#string

Y Ohsugi

http://www.w3.org/2001/XMLSchema#string

Y Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Soluble cytokine receptors are present in normal human urine

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

Interleukin-6 and its receptor: a paradigm for cytokines.

17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Modulation of osteoclast differentiation.

Role of a two-chain IL-6 receptor system in immune and hematopoietic cell regulation.

New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro.

The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro.

Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.

Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

P304

11924-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1996923

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.90.24.11924

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

1993-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242906213

http://www.w3.org/2001/XMLSchema#string

P698

8265649

http://www.w3.org/2001/XMLSchema#string

P921

P932

48097

http://www.w3.org/2001/XMLSchema#string